Human mesenchymal stromal/stem cells (MSCs) are somatic progenitors capable of differentiating into osteocytes, adipocytes, chondrocytes, and other cell types1. MSCs were first isolated from bone marrow and are widely derived from the umbilical cord, adipose tissue, and other tissues2. Because UC-MSCs are easily obtained and exhibit low immunogenicity and immunosuppressive effects, they are widely applied in clinical trials to treat various diseases3,4,5. Although MSC therapy shows promising potential for treating diseases, the therapeutic effects are inconsistent across individuals6. However, the reason for MSC therapy instability is still unclear.
Molecular fluctuations, morphology, differentiation capacity, and therapeutic function comprise MSC heterogeneity. Some studies have also postulated that MSCs constitute subpopulations with different functions7,8 and explored MSC heterogeneity via single-cell RNA sequencing (scRNA-seq)9,10. The results revealed that human UC-MSCs have distinct subpopulations with specific transcriptomic features, whereas few studies have successfully isolated so-called MSC subpopulations. We previously dissected human UC-MSCs into three subgroups according to their signatures via scRNA-seq and bioinformatics analysis, in which the BAMBIhighMFGE8high UC-MSC subpopulation was further purified and functionally tested11. However, this subgroup failed to alleviate lupus nephritis. Thus, it is necessary to test the therapeutic effects of BAMBIhighMFGE8high MSCs in other disorders to understand their authentic functions.
This protocol describes methods for isolating the BAMBIhighMFGE8high subgroup from human UC-MSCs via fluorescence-activated cell sorting (FACS) by flow cytometry and the characteristics of the BAMBIhighMFGE8high subgroup.